Novo Nordisk A/S Common Stock (NVO)

These dividend payers cranked up their payouts over the past decade, and they could do it again.

The Wegovy maker reported positive results from a clinical trial of a next-generation obesity treatment.

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable strength of its diabetes and obesity care segments. The company's flagship weight-loss drug, Wegovy, and the diabetes treatment Ozempic continued their meteoric

FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days.

Novo Nordisk has been in a downtrend for more than a year. But a reversal may be underway, and a rally may follow.

In an otherwise hot stock market, healthcare stocks are underperforming.

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.

The weight loss drug market may reach $95 billion within five years.

Novo Nordisk shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.

EMA approved Rybelsus' label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients.

Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance. However, this impressive growth narrative is punctuated by a revised, lower full-year sales and profit outlook, signaling intensifying competitive pressures

Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for 2025, sending ripples through the global anti-obesity drug market. Despite robust initial half-year performance and the surging demand for weight-loss medications, the Danish giant

A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.

FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA rules.

The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this

One of them is already a leader in the market for weight management drugs, and the other could join this field.

A decade from now, you could regret ignoring these no-brainer stock picks.

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Novo Nordisk announced a "sweeping transformation" Wednesday as the drugmaker contends with challenges in obesity.

ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices.